Lisata Therapeutics Completes Full Enrollment Of Pancreatic Cancer Cohort Of CENDIFOX Trial
Portfolio Pulse from Benzinga Newsdesk
Lisata Therapeutics (NASDAQ:LSTA) has completed patient enrollment for the pancreatic cancer cohort in its Phase 1b/2a CENDIFOX trial. The trial, led by Dr. Anup Kasi at The University of Kansas Cancer Center, is evaluating the safety and efficacy of certepetide in combination with FOLFIRINOX-based therapies for pancreatic, colon, and appendiceal cancers.
June 13, 2024 | 12:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lisata Therapeutics has completed patient enrollment for the pancreatic cancer cohort in its Phase 1b/2a CENDIFOX trial, which is a significant milestone in the development of certepetide for treating various cancers.
The completion of patient enrollment in a clinical trial is a critical milestone that often signals progress and potential future success in drug development. This news is likely to positively impact Lisata's stock price in the short term as it demonstrates advancement in their clinical pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100